News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 181–192 of 243 stories

Tropic's Non-Browning Banana Confirmed as Precision Bred by Defra

Tropic has received Defra confirmation that its gene-edited non-browning banana is precision bred under the Genetic Technology (Precision Breeding) Act 2023. The banana, edited with CRISPR-Cas9 to reduce polyphenol oxidase, still requires Food Standards Agency authorisation before it can be sold in England, and Tropic is targeting commercial introduction from 2027.

Poolbeg Pharma's TOPICAL Trial Cleared to Continue After Interim Safety Review

Poolbeg Pharma has received an independent interim safety review recommending its TOPICAL trial of POLB 001 continue without changes to the study protocol. POLB 001 is an oral drug designed to prevent cytokine release syndrome, a common and potentially dangerous side effect of bispecific antibody and CAR-T cancer therapies that currently has no approved preventative treatment; the review covers safety only and does not establish efficacy. Patient recruitment continues across UK sites including The Christie, The Royal Marsden and University College London Hospitals, with additional centres to be activated.

Funding & Grants23 Sept 2026

Basecamp Research Raises $140M Series C to Advance AI-Designed Therapeutics

Basecamp Research has raised a $140M Series C led by S32, with participation from NVIDIA, Menlo Ventures' Anthology Fund, the NATO Innovation Fund and The Rockefeller Foundation, among others. The funding will train a new generation of its EDEN biological foundation models and advance a pipeline of AI-designed therapeutics towards the clinic, starting with in vivo cell therapy. S32 General Partner Andy Conrad joins the board, and former Biogen executive Richard Pearce has been appointed Chief Business Officer.

John Innes Centre Maps Cereal Immune Receptors Against Blast Fungus

John Innes Centre researchers, working with Kobe University, have mapped at molecular level how a newly discovered class of plant immune receptors called tandem kinase proteins (TKPs) recognise and defend against blast fungus (Magnaporthe oryzae), the most destructive fungal disease of cereal crops worldwide. Using structural analysis, the team bioengineered TKP receptors with dual specificity against both wheat and barley pathogens, demonstrating the class is amenable to engineering and opening a path toward more durable, custom disease resistance in cereals. The study, published in Science Advances, was funded by UKRI/BBSRC.

Scarlet Therapeutics Secures DARPA Agreement Worth Up to $14 Million

Scarlet Therapeutics has entered into an agreement with DARPA worth up to $14 million to develop adaptive smart red blood cells (SRBCs), engineered to sense physiological changes and adjust their activity in response. Scarlet will lead a multidisciplinary consortium including the University of Bristol, Northwestern University and Unicorn Biotechnologies, building on its existing platform for engineering red blood cells to carry therapeutic proteins.

Nuclera Appoints Carl Raimond as CEO, Michael Chen Becomes Chief Scientific and Business Officer

Nuclera has appointed Carl Raimond as Chief Executive Officer, effective immediately, with co-founder and former CEO Dr Michael Chen transitioning to the newly created role of Chief Scientific and Business Officer. Raimond joins from Thermo Fisher Scientific, where he served as President of Proteomic Sciences, having previously been President of Olink Proteomics and helped lead its $3.1 billion acquisition by Thermo Fisher in 2023. The leadership change marks the next phase of Nuclera's growth as the company, known for its cell-free protein synthesis and digital microfluidics platform, sharpens its focus on commercial execution and customer adoption.

Beacon Therapeutics' XLRP Gene Therapy Meets Primary Endpoint in Phase 3 VISTA Trial

Beacon Therapeutics has reported that its gene therapy laru-zova met the primary endpoint in the Phase 3 VISTA trial for X-linked retinitis pigmentosa, with 31% of high-dose patients achieving a 15-letter or greater improvement in low-luminance visual acuity versus none in the untreated control group. The company plans to begin a rolling US biologics licence application later this year.